Zura Bio
NASDAQ: ZURALa Jolla, US · Founded 2021 · 2 known investors
Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously. Its pipeline includes in-licensed assets such as tibulizumab, crebankitug, and torudokimab, advancing through Phase 2 trials for conditions like systemic sclerosis and hidradenitis suppurativa.
Founders & leadership
Zura Bio was founded in 2021 by Someit Sidhu.
SS
Someit SidhuinFounder and Board Member2024–2026
MM
Muzammil MustufainChief Business Officer
KN
Kiran NistalainChief Medical Officer and Head of Development
NG
Neil GrahamNamed on SEC filing
GW
Gary WhaleChief Technology Officer
GN
Garry NeilNamed on SEC filing
MH
Michael HowellNamed on SEC filing
CC
Christopher CabellNamed on SEC filing
AM
Amit MunshiNamed on SEC filing
VB
Verender BadialNamed on SEC filing
JJ
Jennifer JarrettNamed on SEC filing
SS
Steven SchochNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$128.4M disclosed across 2 rounds · 2023–2024
▶$112.5MraisedMay 2024 · 19 investors · BiotechnologyRule 506(b)
▶$112.5MraisedMay 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael HowellExecutive Officer
- Sandeep KulkarniDirector
- Robert LisickiExecutive Officer, Director
- Neil GrahamDirector
- Kiran NistalaExecutive Officer
- Gary WhaleExecutive Officer
- Verender BadialExecutive Officer
- Steven SchochDirector
- Jennifer JarrettDirector
- Someit SidhuDirector
- Amit MunshiDirector
- Kim DavisExecutive Officer
- Arnout Ploos van AmstelDirector
- Parvinder ThiaraDirector
- Offering amount
- $112.5M
- Amount sold
- $112.5M
- Finders' fees
- $6.8M
- First sale
- Apr 2024
- Incorporated
- Corporation, Cayman Islands, 2021
- Federal exemptions
- 06b
▶$15.9MraisedMay 2023 · 21 investors · BiotechnologyRule 506(b)
▶$15.9MraisedMay 2023 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Neil GrahamDirector
- Gary WhaleExecutive Officer
- Garry NeilDirector
- Michael HowellExecutive Officer
- Christopher CabellExecutive Officer
- Amit MunshiDirector
- Verender BadialExecutive Officer
- Jennifer JarrettDirector
- Steven SchochDirector
- Someit SidhuExecutive Officer, Director
- Kim DavisExecutive Officer
- Sandeep KulkarniDirector
- Offering amount
- $80M
- Amount sold
- $15.9M
- Sales commissions
- $2.4M
- First sale
- May 2023
- Incorporated
- Corporation, Cayman Islands, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha15 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView13 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
TipRanks12 shared keywordsFinancial analysis and stock research platform.
Public12 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Simply Wall St12 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Companies competing with Zura Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Zura Bio do?
- Zura Bio is a clinical-stage biotechnology company developing antibody therapies for autoimmune diseases using a dual antagonism strategy that targets multiple immune pathways simultaneously. Its pipeline includes in-licensed assets such as tibulizumab, crebankitug, and torudokimab, advancing through Phase 2 trials for conditions like systemic sclerosis and hidradenitis suppurativa.
- Who founded Zura Bio?
- Zura Bio was founded by Someit Sidhu in 2021.
- Who are Zura Bio's investors?
- Zura Bio's investors include Access Biotechnology, TMG Ventures.
- How much funding has Zura Bio raised?
- Zura Bio has disclosed $128.4M raised across 2 rounds.
- Where is Zura Bio headquartered?
- Zura Bio is headquartered in La Jolla, US.